Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia.
暂无分享,去创建一个
S. Armstrong | G. Peters | S. Korsmeyer | R. Stam | M. D. Den Boer | R. Pieters | J. Meijerink | M. E. Ebus | G. Janka-Schaub | P. Noordhuis | M. D. den Boer
[1] Dan L. Longo,et al. Cancer Chemotherapy and Biotherapy: Principles and Practice , 2001 .
[2] J. Raemaekers,et al. A novel method to compensate for different amplification efficiencies between patient DNA samples in quantitative real-time PCR. , 2001, The Journal of molecular diagnostics : JMD.
[3] G. Peters,et al. Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562 , 1999, British journal of haematology.
[4] D. Arthur,et al. Cytogenetic studies of infant acute lymphoblastic leukemia: poor prognosis of infants with t(4;11) – a report of the Children’s Cancer Group , 1999, Leukemia.
[5] S. Seeber,et al. Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukaemia , 1998, British journal of haematology.
[6] M. D. Boer,et al. Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia–implications for treatment of infants , 1998, Leukemia.
[7] S. Seeber,et al. Assessment of resistance induction to cytosine arabinoside following transfer and overexpression of the deoxycytidylate deaminase gene in vitro. , 1998, Leukemia research.
[8] J. Shuster,et al. Intensive Alternating Drug Pairs After Remission Induction for Treatment of Infants With Acute Lymphoblastic Leukemia: A Pediatric Oncology Group Pilot Study , 1998, Journal of pediatric hematology/oncology.
[9] G. Magni,et al. Pyrimidine nucleotidases from human erythrocyte possess phosphotransferase activities specific for pyrimidine nucleotides , 1997, FEBS letters.
[10] A. Paterson,et al. Sensitivity of acute leukemia cells to cytarabine is a correlate of cellular es nucleoside transporter site content measured by flow cytometry with SAENTA-fluorescein. , 1997, Blood.
[11] M. Volm,et al. Deoxycytidine kinase mRNA expression in childhood acute lymphoblastic leukemia. , 1997, Anti-cancer drugs.
[12] S. Seeber,et al. Constitutive overexpression of the cytidine deaminase gene confers resistance to cytosine arabinoside in vitro. , 1996, Leukemia.
[13] C. A. Blau,et al. Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine. , 1996, Experimental hematology.
[14] H. Hori,et al. Deoxycytidine kinase mRNA levels in leukemia cells with competitive polymerase chain reaction assay. , 1996, Leukemia research.
[15] J. Laliberté,et al. Transfection of murine fibroblast cells with human cytidine deaminase cDNA confers resistance to cytosine arabinoside , 1996, Anti-cancer drugs.
[16] G. Peters,et al. Modulation of metabolism and cytotoxicity of cytosine arabinoside with N-(phosphon)-acetyl-L-aspartate in human leukemic blast cells and cell lines. , 1996, Leukemia research.
[17] M. Greaves. Infant leukaemia biology, aetiology and treatment. , 1996, Leukemia.
[18] C. Pui,et al. Biology and treatment of infant leukemias. , 1995, Leukemia.
[19] R. Pieters,et al. Mononuclear cells contaminating acute lymphoblastic leukaemic samples tested for cellular drug resistance using the methyl-thiazol-tetrazolium assay. , 1994, British Journal of Cancer.
[20] J. Shuster,et al. Frequency and prognostic significance of HRX rearrangements in infant acute lymphoblastic leukemia: a Pediatric Oncology Group study. , 1994, Blood.
[21] J. Downing,et al. 11q23/MLL rearrangement confers a poor prognosis in infants with acute lymphoblastic leukemia. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] N. Heerema,et al. Cytogenetic features of infants less than 12 months of age at diagnosis of acute lymphoblastic leukemia: impact of the 11q23 breakpoint on outcome: a report of the Childrens Cancer Group. , 1994, Blood.
[23] R. Willemze,et al. Role of deoxycytidine kinase in an in vitro model for AraC- and DAC-resistance: substrate-enzyme interactions with deoxycytidine, 1-beta-D-arabinofuranosylcytosine and 5-aza-2'-deoxycytidine. , 1993, Leukemia.
[24] B. Mitchell,et al. Resistance to 1-beta-D-arabinofuranosylcytosine in human T-lymphoblasts mediated by mutations within the deoxycytidine kinase gene. , 1992, Cancer research.
[25] R. Pieters,et al. In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions , 1990 .
[26] P. Sperryn,et al. Blood. , 1989, British journal of sports medicine.
[27] R. Pieters,et al. Adaptation of the rapid automated tetrazolium dye based (MTT) assay for chemosensitivity testing in childhood leukemia. , 1988, Cancer letters.
[28] J. White,et al. Membrane transport influences the rate of accumulation of cytosine arabinoside in human leukemia cells. , 1987, The Journal of clinical investigation.
[29] S. Sallan,et al. Pharmacokinetics of continuous intravenous and subcutaneous infusions of cytosine arabinoside. , 1982, Blood.
[30] J. Wiley,et al. Cytosine arabinoside influx and nucleoside transport sites in acute leukemia. , 1982, The Journal of clinical investigation.
[31] C. N. Coleman,et al. Deoxycytidine kinase: properties of the enzyme from human leukemic granulocytes. , 1975, Blood.
[32] D. Ho,et al. Clinical pharmacology of l‐β‐D‐arabinofuranosyl cytosine , 1971 .
[33] E. Lander,et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia , 2002, Nature Genetics.
[34] C. Cass,et al. Recent advances in the molecular biology of nucleoside transporters of mammalian cells. , 1998, Biochemistry and cell biology = Biochimie et biologie cellulaire.
[35] K. Kishi,et al. Expression of deoxycytidine kinase (dCK) gene in leukemic cells in childhood: decreased expression of dCK gene in relapsed leukemia. , 1998, Leukemia & lymphoma.
[36] L. Frankel,et al. Therapeutic trial for infant acute lymphoblastic leukemia: the Pediatric Oncology Group experience (POG 8493). , 1997, Journal of pediatric hematology/oncology.
[37] E. Frei,et al. Clinical pharmacology of 1-beta-d-arabinofuranosyl cytosine. , 1971, Clinical pharmacology and therapeutics.